Pfizer, Longevity Biotech Gero join hands to discover potential targets for fibrotic diseases
US: Gero has announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
As part of this research collaboration, the companies will leverage Pfizer's expertise and Gero’s technology platform with the aim to identify genes and pathways linked to fibrotic diseases. Pfizer may advance the potential therapeutic targets and would be responsible for further preclinical and clinical development.
“Human data-driven drug discovery avoids the “preclinical trap” and has the potential to identify clinically relevant targets against human (not rodent) diseases. However, genetics-based target identification against age-related diseases is hindered by the irreversible component of human aging,” said Peter Fedichev, CEO of Gero. “Our technology platform allows us to separate irreversible effects of aging from reversible disease phenotypes to potentially identify the most actionable therapeutic targets.”
Gero will receive an upfront payment and is eligible to receive discovery milestone payments if the project progresses.
Read also: Pfizer Pentavalent Meningococcal Vaccine under USFDA review
“We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need.” said Alex Kadet, CBO of Gero. “We believe that combining our platform technology with Pfizer’s extensive disease expertise has the potential to identify high-value targets in this disease area.”
Read also: Pfizer India announces 12-week paternity leave policy for its workforce
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.